Case Study: Decoy Therapeutics accelerates antiviral drug discovery with Google Cloud and GKE

Decoy Therapeutics boosts computational bandwidth 25 to 100-fold with Apigee

Decoy Therapeutics, a preclinical-stage biopharmaceutical company, faced the challenge of scaling its AI-driven antiviral drug discovery. Their research infrastructure was fragmented across local and cloud systems, creating bottlenecks in processing complex protein simulations. To unify their workflows and dramatically accelerate computation, they partnered with vendor Apigee and implemented a solution using Google Cloud products, including Google Kubernetes Engine (GKE) and AlphaFold2.

The solution involved building a unified, GPU-accelerated computational platform orchestrated by GKE. This cloud-native architecture automated protein folding and molecular dynamics simulations. The results were significant: Apigee's solution helped Decoy Therapeutics increase computational bandwidth by 25 to 100-fold. This acceleration compressed traditional drug discovery timelines from five-seven years down to just one year, enabling the company to advance promising pan-viral candidates toward clinical trials at unprecedented speed.

Decoy Therapeutics